Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl

Details Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl

C - Chemistry, Metallurgy

07

D

C07D 471/04 (2006.01) A61K 31/4745 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2736275

The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).

La présente invention concerne des composés de formule (I) dans laquelle R1, R2 et R3 sont tels que définis dans la description, leurs compositions pharmaceutiques et leur utilisation pour le traitement du cancer exprimant la protéine ALK oncogénique, notamment le lymphome anaplasique à grandes cellules (ALCL), le lymphome diffus à grandes cellules B (DLBCL), les tumeurs myofibroblastiques inflammatoires (IMT) et le cancer pulmonaire à grandes cellules (NSCLC).

Affiliated with

Also associated with

Rating

Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2051678